These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 15282678)
41. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine. Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032 [No Abstract] [Full Text] [Related]
42. Pharmacist involvement in a deferoxamine education program for patients with Cooley's anemia. Levine HG; Hanan ZI; Gordon FS; Tomasulo WJ Am J Hosp Pharm; 1979 Jun; 36(6):788-90. PubMed ID: 463895 [TBL] [Abstract][Full Text] [Related]
43. Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes. Hathirat P; Areekul S; Isarangkura P; Chantachum Y J Med Assoc Thai; 1989 Jan; 72 Suppl 1():121-4. PubMed ID: 2732632 [TBL] [Abstract][Full Text] [Related]
44. [Patient compliance in iron-chelating therapy of beta-thalassemia major]. Di Gregorio F; Romeo MA; Tasca R; Passaniti G Minerva Pediatr; 1983 May; 35(10):489-93. PubMed ID: 6877194 [No Abstract] [Full Text] [Related]
45. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)]. Lévy G; Bachelot C; Joannard A; Bost M Arch Fr Pediatr; 1980 May; 37(5):299-303. PubMed ID: 7469704 [TBL] [Abstract][Full Text] [Related]
46. The simple rubber band technic for slow subcutaneous infusion of desferrioxamine. Hathirat P; Sasanakul W; Areekul S; Chantachum Y; Isarangkura P J Med Assoc Thai; 1984 Feb; 67(2):89-92. PubMed ID: 6736830 [No Abstract] [Full Text] [Related]
47. An evaluation of two subcutaneous infusion devices in children receiving palliative care. Breen M Paediatr Nurs; 2006 May; 18(4):38-40. PubMed ID: 16719042 [TBL] [Abstract][Full Text] [Related]
51. [Growth velocity in thalassemic children receiving different protocols of chelating therapy]. Elena MG; Fedele A; Gianino P; Giordanino S; Murru P; Tosi C; Vannelli S Minerva Pediatr; 1992; 44(1-2):41-2. PubMed ID: 1552875 [TBL] [Abstract][Full Text] [Related]
52. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review. Evangeli M; Mughal K; Porter JB Hemoglobin; 2010 Jun; 34(3):305-21. PubMed ID: 20524820 [TBL] [Abstract][Full Text] [Related]
53. Subcutaneous diethylene triamine pentaacetic acid: comparison with desferrioxamine in thalassemic patients with iron overload. Pippard MJ; Jackson MJ; Modell CB Birth Defects Orig Artic Ser; 1988; 23(5B):105-9. PubMed ID: 3390531 [No Abstract] [Full Text] [Related]
54. Intensive iron-chelation in thalassaemia. Br Med J; 1978 Sep; 2(6140):782-3. PubMed ID: 698731 [No Abstract] [Full Text] [Related]
55. Behavioral contracting to improve adherence in patients with thalassemia. Koch DA; Giardina PJ; Ryan M; MacQueen M; Hilgartner MW J Pediatr Nurs; 1993 Apr; 8(2):106-11. PubMed ID: 8509968 [TBL] [Abstract][Full Text] [Related]
56. Subcutaneous infusion: non-metal cannulae vs metal butterfly needles. Torre MC Br J Community Nurs; 2002 Jul; 7(7):365-9. PubMed ID: 12131852 [TBL] [Abstract][Full Text] [Related]
57. Quality of life in thalassemia. Telfer P; Constantinidou G; Andreou P; Christou S; Modell B; Angastiniotis M Ann N Y Acad Sci; 2005; 1054():273-82. PubMed ID: 16339675 [TBL] [Abstract][Full Text] [Related]